Home » Merck Nets Third FDA Approval for Keytruda as Cancer Treatment
Merck Nets Third FDA Approval for Keytruda as Cancer Treatment
Merck received its third FDA-approved use for Keytruda on Monday: a post-chemotherapy treatment for patients head and neck squamous cell carcinoma.
The approval covers a 200 mg fixed dose every three weeks for patients with recurrent or metastatic cancer that already have undergone platinum-containing chemotherapy.
Keytruda already is approved to treat melanoma and lung cancer.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May